Cargando…
Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors
An increasing number of patients develop an atherothrombotic myocardial infarction (MI) in the absence of standard modifiable risk factors (SMuRFs). Monocytes and macrophages regulate the development of atherosclerosis, and monocytes can adopt a long-term hyperinflammatory phenotype by epigenetic re...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338301/ https://www.ncbi.nlm.nih.gov/pubmed/37456854 http://dx.doi.org/10.1016/j.isci.2023.107183 |
_version_ | 1785071598848442368 |
---|---|
author | Mol, Jan-Quinten van Tuijl, Julia Bekkering, Siroon van der Heijden, Charlotte D.C.C. Damen, Sander A.J. Cossins, Benjamin C. van Emst, Liesbeth Nielen, Tim M. Rodwell, Laura Li, Yang Pop, Gheorghe A.M. Netea, Mihai G. van Royen, Niels Riksen, Niels P. El Messaoudi, Saloua |
author_facet | Mol, Jan-Quinten van Tuijl, Julia Bekkering, Siroon van der Heijden, Charlotte D.C.C. Damen, Sander A.J. Cossins, Benjamin C. van Emst, Liesbeth Nielen, Tim M. Rodwell, Laura Li, Yang Pop, Gheorghe A.M. Netea, Mihai G. van Royen, Niels Riksen, Niels P. El Messaoudi, Saloua |
author_sort | Mol, Jan-Quinten |
collection | PubMed |
description | An increasing number of patients develop an atherothrombotic myocardial infarction (MI) in the absence of standard modifiable risk factors (SMuRFs). Monocytes and macrophages regulate the development of atherosclerosis, and monocytes can adopt a long-term hyperinflammatory phenotype by epigenetic reprogramming, which can contribute to atherogenesis (called “trained immunity”). We assessed circulating monocyte phenotype and function and specific histone marks associated with trained immunity in SMuRFless patients with MI and matched healthy controls. Even in the absence of systemic inflammation, monocytes from SMuRFless patients with MI had an increased overall cytokine production capacity, with the strongest difference for LPS-induced interleukin-10 production, which was associated with an enrichment of the permissive histone marker H3K4me3 at the promoter region. Considering the lack of intervenable risk factors in these patients, trained immunity could be a promising target for future therapy. |
format | Online Article Text |
id | pubmed-10338301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103383012023-07-14 Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors Mol, Jan-Quinten van Tuijl, Julia Bekkering, Siroon van der Heijden, Charlotte D.C.C. Damen, Sander A.J. Cossins, Benjamin C. van Emst, Liesbeth Nielen, Tim M. Rodwell, Laura Li, Yang Pop, Gheorghe A.M. Netea, Mihai G. van Royen, Niels Riksen, Niels P. El Messaoudi, Saloua iScience Article An increasing number of patients develop an atherothrombotic myocardial infarction (MI) in the absence of standard modifiable risk factors (SMuRFs). Monocytes and macrophages regulate the development of atherosclerosis, and monocytes can adopt a long-term hyperinflammatory phenotype by epigenetic reprogramming, which can contribute to atherogenesis (called “trained immunity”). We assessed circulating monocyte phenotype and function and specific histone marks associated with trained immunity in SMuRFless patients with MI and matched healthy controls. Even in the absence of systemic inflammation, monocytes from SMuRFless patients with MI had an increased overall cytokine production capacity, with the strongest difference for LPS-induced interleukin-10 production, which was associated with an enrichment of the permissive histone marker H3K4me3 at the promoter region. Considering the lack of intervenable risk factors in these patients, trained immunity could be a promising target for future therapy. Elsevier 2023-06-19 /pmc/articles/PMC10338301/ /pubmed/37456854 http://dx.doi.org/10.1016/j.isci.2023.107183 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mol, Jan-Quinten van Tuijl, Julia Bekkering, Siroon van der Heijden, Charlotte D.C.C. Damen, Sander A.J. Cossins, Benjamin C. van Emst, Liesbeth Nielen, Tim M. Rodwell, Laura Li, Yang Pop, Gheorghe A.M. Netea, Mihai G. van Royen, Niels Riksen, Niels P. El Messaoudi, Saloua Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors |
title | Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors |
title_full | Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors |
title_fullStr | Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors |
title_full_unstemmed | Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors |
title_short | Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors |
title_sort | peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338301/ https://www.ncbi.nlm.nih.gov/pubmed/37456854 http://dx.doi.org/10.1016/j.isci.2023.107183 |
work_keys_str_mv | AT moljanquinten peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT vantuijljulia peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT bekkeringsiroon peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT vanderheijdencharlottedcc peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT damensanderaj peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT cossinsbenjaminc peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT vanemstliesbeth peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT nielentimm peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT rodwelllaura peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT liyang peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT popgheorgheam peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT neteamihaig peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT vanroyenniels peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT riksennielsp peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors AT elmessaoudisaloua peripheralbloodmononuclearcellhyperresponsivenessinpatientswithprematuremyocardialinfarctionwithouttraditionalriskfactors |